0RA Stock Overview
A clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
RAPT Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.76 |
| 52 Week High | US$3.84 |
| 52 Week Low | US$3.62 |
| Beta | 0.40 |
| 11 Month Change | -2.08% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -85.86% |
| 5 Year Change | n/a |
| Change since IPO | -86.67% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0RA | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -3.0% | -0.1% |
| 1Y | n/a | -19.4% | 2.3% |
Return vs Industry: Insufficient data to determine how 0RA performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how 0RA performed against the German Market.
Price Volatility
| 0RA volatility | |
|---|---|
| 0RA Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.3% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: 0RA has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 0RA's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 126 | Brian Wong | www.rapt.com |
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company’s lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer.
RAPT Therapeutics, Inc. Fundamentals Summary
| 0RA fundamental statistics | |
|---|---|
| Market cap | €93.62m |
| Earnings (TTM) | -€109.94m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.9x
P/E RatioIs 0RA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0RA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$118.05m |
| Earnings | -US$118.05m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.38 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 0RA perform over the long term?
See historical performance and comparison